Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 39 - Medicinal preparations containing antigens or antibodies
Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
03/2012
03/21/2012EP2429659A1 Method for detoxification of lipopolysaccharide (lps) or of lipid a of gram-negative bacteria
03/21/2012EP2429658A2 Method for admixing the lipopolysaccharide (lps) of gram-negative bacteria
03/21/2012EP2429584A2 Methods and compositions for treatment
03/21/2012EP2429583A1 Methods and compositions for treating lupus
03/21/2012EP2429582A2 Anti-human cd52 immunoglobulins
03/21/2012EP2429581A1 Enhanced immune response in avian species
03/21/2012EP2429580A1 Method for orthopoxvirus production and purification
03/21/2012EP2429579A1 Immortalized avian cell lines and use thereof
03/21/2012EP2429578A1 Methods of treating or preventing influenza associated illness with oxidative reductive potential water solutions
03/21/2012EP2429577A2 New human rotavirus strains and vaccines
03/21/2012EP2429576A1 Meningococcal vaccine based on lipooligosaccharide (los) and neisseria meningitidis protein
03/21/2012EP2429575A1 Compositions and methods for immunodominant antigens of mycobacterium tuberculosis
03/21/2012EP2320946B1 Allergoids derived from allergenes
03/21/2012EP2167531B1 Streptococcus pneumoniae pilus antigens
03/21/2012EP2074147B1 Antibodies against ccr5 and uses thereof
03/21/2012EP1989551B1 Method of detecting or diagnosing of a neurodegenerative disease or condition
03/21/2012EP1966244B1 Anti-il-6 antibodies preventing the binding of il-6 complexed with il-6ralpha to gp130
03/21/2012EP1957104B1 Influenza vaccines extemporaneously adsorbed to aluminium adjuvants
03/21/2012EP1812067B1 Compositions against sars-coronavirus and uses thereof
03/21/2012EP1688488B9 Bispecific antibody substituting for factor viii
03/21/2012EP1528935B1 Methods for the treatment of an infectious bacterial disease with an anti-lactone or lactone derived signal molecules antibody
03/21/2012EP1515988B1 Dna sequence and recombinant production of the grass pollen allergen phl p4
03/21/2012EP1461428B1 Method for producing hybrid antibodies
03/21/2012EP1436624B1 A method of diagnosis and treatment and agents useful for same
03/21/2012EP1313853B1 Modulation of fas and fasl expression by a synthetic phosphodiester oligonucleotide and an anti-fas antibody
03/21/2012EP1088077B2 Newcastle disease virus infectious clones, vaccines and diagnostic assays
03/21/2012CN1756843B Streptococcus pyogenes antigens
03/21/2012CN1554764B Recombinant mva virus, and the use thereof
03/21/2012CN102388139A Modulation of toll-like receptor 5 expression by antisense oligonucleotides
03/21/2012CN102388067A Targeted binding agents directed to cd105 and uses thereof
03/21/2012CN102388066A Antibody molecules having binding specificity for human IL-13
03/21/2012CN102388063A Methods for inducing transplantation tolerance
03/21/2012CN102387814A Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases
03/21/2012CN102387813A Identification, optimization and use of cryptic hla-a24 epitopes for immunotherapy
03/21/2012CN102387808A Immunopotentiating composition and process for producing same
03/21/2012CN102382872A Inactivated vaccine against Gram-negative bacteria, and its preparation method and application
03/21/2012CN102382853A Preparation method of vaccine mucosal immune adjuvant molecules
03/21/2012CN102382845A Method for producing porcine parvovirus antigen and its product
03/21/2012CN102382179A Peptide sequences and compositions
03/21/2012CN102380098A Combination therapy for the treatment of ocular neovascular disorders
03/21/2012CN102380097A Peptide-based passive immunization therapy for treatment of atherosclerosis
03/21/2012CN102380096A Medicine combination containing fusion protein for suppressing angiogenesis and application
03/21/2012CN102380095A FMD trivalence polypeptide vaccine and preparation method and application thereof
03/21/2012CN102380094A Application of specific polypeptide to preparation of rabies vaccine
03/21/2012CN102380093A Method for producing newcastle disease living vaccines by utilizing passage fibroblasts
03/21/2012CN102380092A Inactivated vaccine for infectious coryza of chickens
03/21/2012CN101716341B Human diploid cell inactivated rabies vaccine and preparation method thereof
03/21/2012CN101555283B Antibodies to non-functional p2x7 receptor, diagnosis and treatment of cancers and other conditions
03/21/2012CN101355963B Marked bovine viral diarrhea virus vaccines
03/21/2012CN101297966B Tumor vaccine for intestinal cancer containing rich chaperone-antigenic peptide complexes and preparation thereof
03/21/2012CN101164543B Acyl pseudopeptides bearing a functionalised auxiliary spacer
03/21/2012CN101130071B Vaccine
03/21/2012CN101048502B Modified human hepatitis c virus genomic RNA having autonomous replicative competence
03/20/2012US8138323 Cytokines; side effect reduction; bactericides; antitumor agents; anticarcinogenic agents
03/20/2012US8138318 Hepatitis B pre-S2 nucleic acid
03/20/2012US8138314 Compositions and methods of monoclonal and polyclonal antibodies specific for T cell subpopulations
03/20/2012US8138311 Modified proteins, designer toxins, and methods of making thereof
03/20/2012US8138310 Chimeric CD154 polypeptides
03/20/2012US8138154 Biglycan and related therapeutics and methods of use
03/20/2012US8138141 HMG1 antibody for treating inflammatory conditions
03/20/2012US8137991 Methods of reducing angiogenesis of age-related macular degeneration (AMD) or choroidal neovascularization by an anti-carboxyetheylpyrrole (CFP) antibody
03/20/2012US8137989 Method for delivering a cytokine using a colloidal metal
03/20/2012US8137935 Method for isolating endotoxins
03/20/2012US8137932 Method for the stabilization of chimeric immunoglobulins or immunoglobulin fragments, and stabilized anti-EGP-2 scFv fragment
03/20/2012US8137931 Fusion proteins of HIV regulatory/accessory proteins
03/20/2012US8137921 Homogeneous time resolved fluorescence based test system for Paramyxoviridae
03/20/2012US8137915 Genes involved in intestinal inflammatory diseases and use thereof
03/20/2012US8137908 Mesothelin vaccines and model systems
03/20/2012US8137904 Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
03/20/2012US8137687 Implantable medical device having a coating of a biocompatible polylactone from N-substituted 4-aza-caprolactone
03/20/2012US8137681 Polyanionic polymer adjuvants for Haemophilus influenzae B saccharide vaccines
03/20/2012US8137680 Analysis of saccharide vaccines without interference
03/20/2012US8137679 Immunogen adherence inhibitor directed to Lactobacillus organisms and method of making and using it
03/20/2012US8137678 Canine lyme disease vaccine
03/20/2012US8137677 Non-protein stabilized clostridial toxin pharmaceutical compositions
03/20/2012US8137676 Attenuated viruses comprising modified NS1 genes, having an impaired ability to antagonize the cellular interferon response; decreased in vivo replication, virulence and increased attenuation; live cancer vaccines
03/20/2012US8137675 Bont/a peptides and methodsof predicting and reducing immunoresistance to botulinum toxin therapy
03/20/2012US8137674 Compositions comprising HPV polypeptides and immunoenhancement peptides for the treatment and prevention of cervical cancer
03/20/2012US8137673 Nucleic acids and proteins from Streptococcus groups A & B
03/20/2012US8137672 Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody
03/20/2012US8137671 Anti-IL-17F antibodies
03/20/2012US8137670 Method of identifying membrane IgE specific antibodies and use thereof for targeting IgE producing precursor cells
03/20/2012US8137669 Elimination of heterogeneous or mixed cell population in tumors
03/20/2012US8137667 Fully human antibodies against human 4-1BB
03/20/2012CA2622180C Method for generating f(ab')2 antibody fragments
03/20/2012CA2521051C Microfluidized oil-in-water emulsions and vaccine compositions
03/20/2012CA2509484C Stabilized immunogenic hbc chimer particles
03/20/2012CA2505869C Live attenuated vaccine against porcine pleuropneumonia
03/20/2012CA2474801C Human monoclonal antibody fab fragments directed against hcv e2 glycoprotein and endowed with in vitro neutralizing activity
03/20/2012CA2455455C Method and system to determine revised dosage
03/20/2012CA2453300C Chimeric chains that code for proteins that induce effects directed against viruses
03/20/2012CA2446981C Method for obtaining antigen-specific tr1 regulatory lymphocytes
03/20/2012CA2441292C Equine herpesvirus vaccine
03/20/2012CA2435683C Hybridoma cell line g250 and its use for producing monoclonal antibodies
03/20/2012CA2429172C Novel mutant allergens
03/20/2012CA2410901C Methods and compounds for controlled release of recombinant parvovirus vectors
03/20/2012CA2379564C Structural protein of adeno-associated virus with modified chromatographic properties, its production and use
03/20/2012CA2352603C Gp120 mutants and biological applications
03/20/2012CA2334857C Interferon inducing genetically engineered attenuated viruses
03/20/2012CA2296842C Ligands, including antibodies, showing reactivity against endocrine cells
1 ... 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 ... 1823